140 related articles for article (PubMed ID: 37732172)
1. Clinical Manifestations and Risk Factors of Tigecycline-Associated Thrombocytopenia.
Zhu Y; Zhao F; Jin P
Infect Drug Resist; 2023; 16():6225-6235. PubMed ID: 37732172
[TBL] [Abstract][Full Text] [Related]
2. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database.
Guo M; Liang J; Li D; Zhao Y; Xu W; Wang L; Cui X
Thromb J; 2022 Mar; 20(1):12. PubMed ID: 35248072
[TBL] [Abstract][Full Text] [Related]
3. Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: A multicenter retrospective study in China.
Leng B; Shen C; Gao T; Zhao K; Zhao X; Guo Y; Wu J; Yang J; Fang W; Zhang J; Zhang Y; Sun C; Duan L; Huang J; Qi Y; Yan G
Front Pharmacol; 2022; 13():943674. PubMed ID: 36304151
[No Abstract] [Full Text] [Related]
4. Risk Factors for Tigecycline-Associated Hypofibrinogenemia.
Liu J; Yan Y; Zhang F
Ther Clin Risk Manag; 2021; 17():325-332. PubMed ID: 33888987
[TBL] [Abstract][Full Text] [Related]
5. Tigecycline-associated hypofibrinogenemia in a real-world setting.
Campany-Herrero D; Larrosa-Garcia M; Lalueza-Broto P; Rivera-Sánchez L; Espinosa-Pereiro J; Mestre-Torres J; Pigrau-Serrallach C
Int J Clin Pharm; 2020 Aug; 42(4):1184-1189. PubMed ID: 32504166
[TBL] [Abstract][Full Text] [Related]
6. Hematological adverse events associated with anti-MRSA agents: a real-world analysis based on FAERS.
Yu X; Zhou X; Li M; Zhao Y
Expert Opin Drug Saf; 2024 Jan; ():1-11. PubMed ID: 38251915
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of tigecycline-associated fibrinogen reduction in patients with renal transplantation: a case-control study.
Xie W; Ma K; Xu Z; Xie J; Lu X; Wang X
Transl Androl Urol; 2022 Oct; 11(10):1410-1418. PubMed ID: 36386261
[TBL] [Abstract][Full Text] [Related]
8. Severe Coagulation Disorder and Thrombocytopenia Associated with Tigecycline - Case Report and Review of Literature.
Giryes S; Azzam ZS; Ismael-Badarneh R; Krivoy N; Berger G
Curr Drug Saf; 2017; 12(1):7-9. PubMed ID: 27659942
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia.
Lei H; Liu X; Li Z; Wang C
J Chemother; 2023 Jul; 35(4):292-297. PubMed ID: 35904191
[TBL] [Abstract][Full Text] [Related]
11. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Zhang L; Cai X; Peng F; Tian S; Wu X; Li Y; Guo J
Front Pharmacol; 2023; 14():1182644. PubMed ID: 37351509
[No Abstract] [Full Text] [Related]
12. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.
Wei C; Liu Y; Jiang A; Wu B
Int J Clin Pharm; 2022 Jun; 44(3):709-716. PubMed ID: 35364753
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for tigecycline-induced hypofibrinogenaemia.
Zhang Q; Wang J; Liu H; Ma W; Zhou S; Zhou J
J Clin Pharm Ther; 2020 Dec; 45(6):1434-1441. PubMed ID: 32860258
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
Hu J; Xiao YH; Zheng Y; Lai YX; Fang XL; Fang Q
Eur J Clin Pharmacol; 2020 Jul; 76(7):913-922. PubMed ID: 32355990
[TBL] [Abstract][Full Text] [Related]
15. Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury Among Patients in China: A 3-year Retrospective Study as Assessed by the Updated RUCAM.
Shi X; Zuo C; Yu L; Lao D; Li X; Xu Q; Lv Q
Front Pharmacol; 2021; 12():761167. PubMed ID: 34795591
[No Abstract] [Full Text] [Related]
16. Clinical Characteristics of Hospitalized Neonates With Hypofibrinogenemia: A Retrospective Cohort Study.
Zhou W; He Y; Li Q; Li Y; Su Y; Yan L
Front Pediatr; 2020; 8():589. PubMed ID: 33072665
[No Abstract] [Full Text] [Related]
17. [Clinical predictive value of short-term dynamic changes in platelet counts for prognosis of sepsis patients in intensive care unit: a retrospective cohort study in adults].
Zhou Z; Xie Y; Feng T; Zhang X; Zhang Y; Jin W; Tian R; Wang R
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Mar; 32(3):301-306. PubMed ID: 32385993
[TBL] [Abstract][Full Text] [Related]
18. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.
Niwa T; Suzuki A; Sakakibara S; Kasahara S; Yasuda M; Fukao A; Matsuura K; Goto C; Murakami N; Itoh Y
Clin Ther; 2009 Oct; 31(10):2126-33. PubMed ID: 19922883
[TBL] [Abstract][Full Text] [Related]
19. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature.
Fan Q; Huang W; Weng Y; Xie X; Shi Z
Medicine (Baltimore); 2020 Oct; 99(43):e22638. PubMed ID: 33120753
[TBL] [Abstract][Full Text] [Related]
20. Tigecycline-related pancreatitis: a review of spontaneous adverse event reports.
Okon E; Engell C; van Manen R; Brown J
Pharmacotherapy; 2013 Jan; 33(1):63-8. PubMed ID: 23307547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
